National Cancer Institute-designated cancer centers should lead the way
Chapel Hill - A family of proteins is yielding new information about how it contributes to the development of gastrointestinal disease and cancer. A team of UNC scientists reports that in pre-clinical models, the absence of a protein called NLRP12 significantly increases susceptibility to colitis-associated colon cancer.
UNC Health Care will offer free screenings during Oral, Head and Neck Cancer Awareness Week, on Wednesday, April 25, from 1 - 4 p.m. in the Ear, Nose, & Throat Clinic on the ground floor of the N.C. Neurosciences Hospital.
Chapel Hill, NC – In a paper published today in the journal Cell, a team from the University of North Carolina at Chapel Hill unveils the first broad-based test for activation of protein kinases “en masse”, enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.
Chapel Hill - Anyone who’s tried a weekend home improvement project knows that to do a job right, you’ve got to have the right tools. For cells, these “tools” are proteins encoded by genes.
Dr. Nancy DeMore and UNC colleagues present triple-negative breast cancer finding at national meeting
Nancy DeMore, MD, and colleagues presented an abstract at the recent Society of Surgical Oncology 65th annual cancer symposium held in Orlando, Florida in March. Dr. DeMore is an associate professor of surgery and a member of UNC Lineberger.
UNC Cancer Care’s neuro-oncology program will recognize Ependymoma Awareness Day on April 19th, as part of the program’s overall efforts to increase public awareness of this rare tumor and the need for clinical studies to improve early diagnosis, standardize treatment and improve the health status of those living with this disease.
James P. Evans, MD, PhD, Bryson Distinguished Professor of Genetics and Medicine, is quoted in recent articles in The News & Observer and the Scientific American blog.
UNC-led team offers clinical, research agenda
Chapel Hill - In a clinical trial of an experimental drug to treat thyroid cancer, UNC and six other institutions report the first evidence in this tumor that targeting therapy to an oncogene documented to be present in the patient receiving therapy may be associated with clinical benefit.